Skip to main content
Premium Trial:

Request an Annual Quote

David C. U Prichard, William Fletcher, George Barrett, William Marth, Amir Elstein, Marvin Samson, Suzanne Nora Johnson, David Ketsdever, Pamela Joy Barton, Joseph Shaw, Carl Goldfischer, Terry Spraker, Donald Harrison

David C. U’Prichard, venture partner of Apax Partners, president of Druid Consulting, and a member of the board of directors of Invitrogen, was recently elected to the board of directors of Ben Franklin Technology. He will serve through January 2006, the group said.


William Fletcher, president and CEO of Teva North America, has been named chairman of the company, the company said last week. George Barrett, currently president and CEO of Teva Pharmaceuticals USA, will be promoted to president and CEO of Teva North America and will become Teva Group vice president. William Marth, currently executive vice president of Teva USA, will become president and CEO of Teva Pharmaceuticals USA. Additionally, Amir Elstein was named Teva Group vice president for biogenerics and Marvin Samson will assume the role of Teva’s vice president for injectables.


Suzanne Nora Johnson was named vice chairman of Goldman Sachs, the company said this week. Johnson currently serves as head of Goldman Sachs’ global investment research division and is chairman of the firm’s global markets institute and will retain those positions. Johnson also serves on the boards of the Carnegie Institution of Washington, the University of Southern California, RAND Health, Technoserve, and Women’s World Banking.


David Ketsdever was named CEO of SVB Alliant, the investment banking subsidiary of Silicon Valley Bancshares, the company said this week. He will oversee the subsidiary’s M&A and private placement activities. Ketsdever joins SVB Alliant from Green Ridge Systems, where he was founder and CEO. Previously, he was managing director of Merrill Lynch’s technology investment banking team, and head of its global software group.


Patrick Barnabe was appointed president of Viropro Pharma of Montreal, the company said this week.


Martin Duvall joins MGI Pharma as senior vice president the Minneapolis company said this week. Duvall was previously vice president for global medical and marketing for taxotere and new cytotoxics at Aventis.


Pamela Joy Barton was named vice president of Nabi Biopharmaceuticals of Boca Raton, Fla., the company said this week. Barton previously was at Sosei where she was vice president of business development, US and European alliance management, and intellectual property.


Joseph Shaw was named CEO of OpGen of Madison, Wisc., the company said this week. Shaw previously served as president of Bank On A Cure, a global study project of the International Myeloma Foundation. Shaw also served as CEO and chairman of the board of Quantech, a biosensor technology company, and CEO of Cathra International, a bacteriological testing company.


Mel Backlin joined Spectranetics of Colorado Springs, Colo., as director of sales. Previously, he was western regional sales manager for Possis Medical.


Nayan Nanavati, formerly at Paraxel, joins Suven Life Sciences of India as president and CEO, the company said this week.


Carl Goldfischer of Bay City Capital, Terry Spraker of Aberdare Ventures, and Donald Harrison of Charter Life Sciences will join EnteroMedics’ board of directors after the firm closed a $16.9 million stock financing this week, the company said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more